Patient-friendly peptide education
General peptide therapy, clinics, safety, brands and long-tail topics.
Recently published
RNA came to prominence during COVID-19 with mRNA vaccines saving millions of lives worldwide. Since then, the technology has evolved with some developers now focusing on personalized mRNA therapeutics rather t…
Read guide →A July report by a team of Jefferies analysts paints an upbeat picture for contract development and manufacturing organizations (CDMOs). Miyabi Yamakita and colleagues reported rising demand for the services o…
Read guide →In addition to COVID-19, viral diseases that are driving the development of mRNA-based vaccines range from influenza to genital herpes. These vaccines are forthcoming because mRNA development platforms are ver…
Read guide →Throughout his career, Luke Dannenberg, PhD, has held multiple positions in industry and academia that have put him in close proximity to oligonucleotide technologies. Trained as a scientist, he transitioned i…
Read guide →Chemify and Dewpoint Therapeutics have announced a partnership today to apply groundbreaking chemistry artificial intelligence (AI) to accelerate the discovery of molecules targeting cancer and neurodegenerati…
Read guide →The global synthetic biology market is projected to reach $30.7 billion by 2026 from $9.5 billion in 2021, at a compound annual growth rate of 26.5% during the forecast period, according to a report from Marke…
Read guide →In 1981, Genetic Engineering and Biotechnology News launched as the newspaper of record for the fledgling biotechnology industry. Publications come and go, but GEN has stayed the course for the past 40 years, …
Read guide →A Cleveland Clinic-led team of scientists and physicians has discovered that the immune checkpoint protein VISTA can directly turn off tumor-fighting T cells during immunotherapy and resist treatment. The team…
Read guide →Imagine a future where rare diseases and devastating cancers can be swiftly treated with therapies produced directly in the clinic and tailored to a patient’s unique genetic profile. Common conditions could be…
Read guide →Time: RNA-based therapeutics continue to impress the scientific community with rapid production, speed-to-market, and efficacious results. While conventional mRNA strategies have paved the way for this groundb…
Read guide →Dive Brief: - Sanofi will advance an experimental inflammatory disease drug into Phase 2 clinical testing after its biotechnology company partner Kymera Therapeutics reported Wednesday what it described as enc…
Read guide →April 15, 2013 (Vol. 33, No. 8) RNAi research has capitalized on the ability to design and deliver small interfering RNAs (siRNAs) or short hairpin RNAs (shRNAs) to knock down expression of target genes with s…
Read guide →Anthropic has released Claude Science, an AI workbench for scientists that consolidates fragmented research tools, including over 60 scientific databases and connectors pre-configured for genomics, proteomics,…
Read guide →Once labeled the “disease of kings” because of its association with consuming rich foods and alcohol, gout has emerged as a royal pain to a growing number of people. A 2024 study showed the prevalence of the m…
Read guide →Biomarker development is hardly coextensive with drug development, but in every developmental stage—from exploratory research to clinical trial to therapeutic application—there is significant overlap. As medic…
Read guide →A study headed by researchers at the Centre for Genomic Regulation (CRG) in Barcelona has provided for the first time evidence that a single drug, already licensed for medical use, can stabilize nearly all mut…
Read guide →A novel strategy developed by scientists at Rice University allows scientists to zoom in on tiny segments of proteins inside living cells, revealing localized environmental changes that could indicate the earl…
Read guide →Some drug treatments, particularly those that include high-dose protein-based therapeutics, are only available as an intravenous (IV) infusion. These protein therapeutics, which need to be delivered as dilute …
Read guide →Insmed (NASDAQ: INSM) is breathing easier since the FDA has approved the company’s Brinsupri™ (brensocatib 10 mg and 25 mg tablets) as the first drug authorized to treat non-cystic fibrosis bronchiectasis (NCF…
Read guide →Until recently, protein-protein interactions (PPIs) have been considered essentially “undruggable,” in part because of the presumed featurelessness of the interface between protein partners. But PPIs play a hu…
Read guide →Browse by subject
Each topic opens a crawlable collection of related articles and resources.